AMLX · Amylyx Pharmaceuticals Inc
United States · RS rating 88 · As of 2026-10-14
| Price | 27.03 USD |
|---|---|
| 1-day change | +0.7% |
| RS rating (overall / 1M / 3M / 12M) | 88 / 13 / 96 / 94 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 40 / 41 / 48 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +18.9% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +31.9% |
| Market cap (USD) | $1.9B |